SinoMab BioScience RSI
Was ist das RSI von SinoMab BioScience?
RSI von SinoMab BioScience Limited ist 28.14
Was ist die Definition von RSI?
Der relative Stärke-Index (RSI 14) ist ein Momentumindikator, der die Größe von Gewinnen und Verlusten über einen bestimmten Zeitraum vergleicht, um die Geschwindigkeit und die Änderung von Preisbewegungen eines Wertpapiers zu messen.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit rsi ähnlich SinoMab BioScience
- Polished.com Inc hat RSI von 28.11
- Re:NewCell AB (publ) hat RSI von 28.12
- TechnipFMC plc hat RSI von 28.12
- Raj Television Network hat RSI von 28.12
- mutares AG hat RSI von 28.13
- Wai Hung hat RSI von 28.13
- SinoMab BioScience hat RSI von 28.14
- Devon hat RSI von 28.15
- UBS ETF (CH) - Palladium hat RSI von 28.15
- Manolete Partners Plc hat RSI von 28.16
- OptimizeRx hat RSI von 28.16
- Chevron hat RSI von 28.16
- Continental AG hat RSI von 28.17